Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia
ConclusionsLomitapide demonstrated promising effectiveness in paediatric HoFH patients. Adverse events were manageable, and the clinical profile of the drug is apparently similar to that in adult patients.FundingAmryt Pharma.
Conclusion: Use of RAS blockers (ACEI or ARB) in uncomplicated as well as complicated hypertensive patients with type 2 diabetes is sub-optimal. Most of the patients are on one drug and prescription of ≥3 drugs are rare. Statins are prescribed in only a half. PMID: 31321925 [PubMed - in process]
Publication date: August 2019Source: Nutrition, Metabolism and Cardiovascular Diseases, Volume 29, Issue 8Author(s): Marialaura Bonaccio, Augusto Di Castelnuovo, Simona Costanzo, Mariarosaria Persichillo, Amalia De Curtis, Chiara Cerletti, Maria Benedetta Donati, Giovanni De Gaetano, Licia Iacoviello
Publication date: Available online 19 July 2019Source: Pharmacological ResearchAuthor(s): Chiara Pavanello, Andrea Baragetti, Adriana Branchi, Liliana Grigore, Samuela Castelnuovo, Eleonora Giorgio, Alberico L. Catapano, Laura Calabresi, Monica GomaraschiAbstractLysosomal acid lipase (LAL) is responsible for the hydrolysis of cholesteryl esters (CE) and triglycerides (TG) within the lysosomes; generated cholesterol and free fatty acids (FFA) are released in the cytosol where they can regulate their own synthesis and metabolism. When LAL is not active, as in case of genetic mutations, CE and TG accumulate in the lysosomal c...
Introduction: Statins are prescribed for patients with cardiovascular disease (CVD), along with the recommendation of adopting healthy diets. This stufy aimed to evaluate the independent and the combined effect of statins and Mediterranean diet (MD) towards mortality risk in subjects with previous CVD by using real-life data from a population-based prospective cohort. We performed a longitudinal analysis on 1,180 subjects (mean age 67.7 ± 10) with prior CVD at enrollment in the Moli-sani study and followed up for 7.9 years (median).
This study investigated the effects of statin in AF patients who experienced acute ischemic stroke.MethodsData from patients with AF experiencing first-ever ischemic stroke between 2001 and 2010 were collected from the Taiwan National Health Insurance Research Database and categorized into non-statin and statin groups. The statin group was further divided into pre-stroke statin (those who began statin therapy before stroke) and post-stroke statin (those who began statin therapy after stroke) groups. The risks for recurrent ischemic stroke, coronary artery disease (CAD), intracranial hemorrhage (ICH), and 1-year mortality w...
Hypertriglyceridemia (HTG) is associated with increased cardiovascular disease (CVD) risk. However, the cost burden of HTG-related CVD in high-risk US adults on statins has not been well characterized.
Conclusion The prevalence of statin induced new onset of diabetes is 7.03%. The main risk factors identified in the study were in older patients (≥60 years), rosuvastatin therapy, high dose and longer duration of statin therapy. PMID: 31311373 [PubMed - as supplied by publisher]
Here ’s the new list of what your health insurance plan might cover next year under Trump Treasury’s broadened definition of preventative care services.
Conclusion: Statin can be used as an adjuvant to erythropoietin in management of anemia in patients of chronic kidney disease, who show hyporesponsiveness to increased doses of erythropoietin, by its anti-inflammatory properties. PMID: 31313547 [PubMed - in process]
Authors: Iyengar SS, Bansal M, Sawhney J, Wander G, Narasingan SN, Chandra KS, D P, Nair T, Krishnakumar B, Deshpande N, Bardoloi N, Shetty S, Desai N, Pancholia AK, Swamy A Abstract The burden of atherosclerotic cardiovascular (CV) disease is alarmingly high and increasing in our country. Dyslipidemia is one of the major modifiable risk factors, and INTERHEART study showed that dyslipidemia had the highest population attributable risk for myocardial infarction. In the management of dyslipidemia, low-density lipoprotein cholesterol (LDL-C) is the primary therapeutic target. In addition to therapeutic lifestyle chan...